Health equity, sickle cell disease, and the thoughtful use of artificial intelligence and social media are among the key themes to be presented at the annual meeting of the American Society of Hematology.
The first-in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial hypercholesterolemia.